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Immunotoxicity encompasses both reduced and heightened immune function. Diverse chemicals
can impair functioning of the immune system. Both monographs and books have been devoted
to detailed descriptions of immunotoxicity. This paper gives a brief overview of the methods
currently used to assess the immunotoxic potential of chemicals. It also discusses the trend
toward the use of alternative methods to mammalian models, such as feral species, in vitro
assays, and computational models. The strategy of using a tier approach to screen chemicals for
immunotoxicity is described, together with the rationale for, and limitations of, this approach.
Interpretation of data with regard to clinical disease and human health is addressed. The immune
system poses substantial complexities in this regard as the system has functional reserve and
functional redundancy. Environ Health Perspect 106(Suppl 2):533-540 (1998). http://ehpnetl.
niehs.nih.gov/docs/1998/Suppl-2/533-540karoI/abstract.html
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Introduction
The immune system is a complex, multi-
component system that comprises lym-
phoid organs located throughout the body
and interacting, specialized cells. The major
lymphoid organs are the spleen, thymus,
lymph nodes, bone marrow, and areas of
the intestine (Peyer's patches). The major
cell type is the lymphocyte; accessory cells
include macrophages, natural killer (NK)
cells, eosinophils, basophils, dendritic cells,
andepithelial cells, amongothers.
The immune system functions to
protect against both the external environ-
ment and the internal development of
nonself neoplasms. A branch ofimmunol-
ogy designated tumor immunology is
devoted to the study of the immune
responses acquired to tumor antigens and
the nature ofthe antigens on tumor cells
that induce the immune responses.
Dysfunction ofthe immune system results
in increased incidence and severity of
infection, increased reactivity toward envi-
ronmental agents (hypersensitivity), and
increased development oftumors.
The organs, tissues, cells, and mole-
cules of the immune system interact to
provide a coordinated immune response.
Lymphocytes circulate among lymphoid
organs throughout the body. Through sur-
face receptors, they recognize three-dimen-
sional molecular configurations. Upon
engagement of surface molecules with
structures having complementary confor-
mation, lymphocytes become activated.
They proliferate, yielding generations of
cells capable of recognizing and respond-
ing to the same antigen upon future
encounter (1).
The two main populations oflympho-
cytes are B lymphocytes and T lympho-
cytes. Both types ofcells function through
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recognition ofantigens; B cells recognize
antigen in its native form, whereas T lym-
phocytes recognize processed antigen.
Encounter of B cells with complementary
antigen results in cell activation, differenti-
ation into plasma cells, and secretion of
antibodies that recognize the stimulatory
antigen. The five main classes ofantibody
are IgM, IgG, IgA, IgE, and IgD. IgG is
found in high concentrations in the blood,
approximately 12 mg/ml, whereas IgE is
found in verylow concentrations, about 20
ng/ml. In general IgA, IgG, and IgM have
a protective function by facilitating phago-
cytosis ofparticulate antigen and activation
ofcomplement. IgE is the major antibody
class involved in hypersensitivity reactions.
T cells recognize segments ofantigen in
association with products ofthe major his-
tocompatibility complex. There are two
main classes ofT lymphocytes that differ in
function (1). Cytotoxic T cells destroy
infected host cells; helper T cells (Th cells)
function through production ofchemotactic
or proinflammatory cytokines. Cytokines
are biologically active peptides, produced by
a variety ofcell types, that modulate the
function ofcells in immunological reactions
including host resistance (HR) and regula-
tion ofthe immune response. There are two
main populations ofTh cells. In mice and
in humans, cytokines secreted by Thl cells
stimulate a delayed-type hypersensitivity
(DTH) response; those released byTh2 cells
stimulate IgE production and favor an
immediate-onset reaction.
Immunotoxicity can be defined as the
adverse effect ofchemicals or agents on the
immunesystem. The effect maybe increased
immune activity, manifested as either hyper-
sensitivity or autoimmunity, or decreased
immune function, with reduced ability to
combat infectious agents or tumors.
Diverse agents have been associated
with immunosuppression in animals,
including chemicals, bioaerosols (bacteria,
algae, fungi), and physical agents such as
ultraviolet light (1). Heightened immune
responsiveness, including allergy, may result
from chemical exposure. The two most
important allergic diseases in the context of
occupational and environmental exposures
are allergic contact dermatitis (ACD) and
respiratory hypersensitivity (RH). ACD is
prevalent in certain industries and can be
induced by hundreds ofdiverse chemicals.
T lymphocytes are central to the pathogen-
esis ofACD. RH is caused by relatively few
low molecular weight chemicals (i.e., less
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than 1 kDa) (2), but by numerous high
molecular weight environmental agents.
Allergic diseases caused by environmental
agents are widespread. The incidence in the
Western world ofone such disease, asthma,
is increasing. The reason for the increase is
unclear, although environmental agents and
delayed exposure ofchildren to childhood
viral infections have been suggested as
contributing factors (3).
Allergy develops in two stages. Initial
encounter with the agent results in a pri-
mary immune response and a state of
heightened responsiveness to future
encounter with that agent. Subsequent
exposure ofthe now sensitized individual to
the same allergen results in a secondary
immune response that is both more vigor-
ous and accelerated. The secondary response
may be a production and release ofspecific
antibodies, cytokines, or other inflamma-
tory mediators to produce inflammation
and allergic response. Differences in suscep-
tibility to hypersensitivity relate to the
immunologic repertoire ofthe individual,
i.e., the ability of the immune system to
recognize and respond to small, structurally
simple antigens.
TierApproach to Testing
Due in part to the complexity of the
immune system, assessment oftest chemi-
cals for immunotoxicity utilizes a variety of
immune assays. The test methods, as well
as the principles supporting the methodol-
ogy, have been thoroughly described (4). A
tiered approach to testing is undertaken
that includes examination ofpathological
changes and assessment offunctional activ-
ity (5). Assays have been conducted in
mice and rats and found to be robust and
reproducible. Correlations between test
outcomes and altered host defense have
been studied (6) to reduce the dependence
on multiple assays and to determine the
ability ofthe tests to predict immunologic
disease in humans.
Tier I
Tier I assesses three aspects of immune
system integrity: cell-mediated immunity
(CMI), humoral immunity (HI), and
immunopathology (Table 1). Test chemi-
cals are administered in doses that do not
produce overt toxicity.
Cell-Mediated Immune System
Cell-mediated immunity is assessed by
measurement ofthe blastogenesis and pro-
liferation oflymphocyte populations when
stimulated with nonspecific mitogens (7).
Table 1. Tier approach to detecting immune system
toxicity in rodents.
Tier tests
Hematology (e.g., cell counts)
Organ weights
Organ cellularity
Lymphoid organ histology
IgM antibody PFC
Lymphocyte blastogenesis
T-cell mitogens(PHA, ConA)
T-cell mixed leukocyte response
B-cell mitogens (LPS)
Natural killercell activity
Tier II tests
Splenic B, Tcell counts
lgG antibody PFC count
Cytotoxicity Tcells; or DTH
HR assay
Syngeneic tumorcells
PYB6 sarcoma (tumor incidence)
B16F10 melanoma (lung burden)
Bacterial models
Lysteriamonocytogenes(morbidity)
Streptococcus(morbidity)
Viral models
Influenza (morbidity)
Parasite models
Plasmodium yoe/ii(parasitemia)
T cells are tested by incubation with
phyto-hemagglutinin (PHA) or with con-
canavalin A (ConA); B cells are tested by
incubation with lipopolysaccharide (LPS).
These assays are performed by mixing iso-
lated spleen cells from rats or mice with the
mitogen in several concentrations. 3H-
Thymidine is added 4 to 18 hr prior to cell
harvest. Cells are harvested and radioactiv-
ity is assessed. Results are dependent on
numerous biochemical events that culmi-
nate in DNA synthesis and cell division.
Such tests for CMI have been used to
assess lymphocyte function in patients with
immunodeficiency disease, notably in
asymptomatic acquired immunodeficiency
syndrome (AIDS) patients.
Another test of CMI is the mixed
lymphocyte response (MLR). This assay
measures the proliferation oflymphocytes
when stimulated by allogeneic cells. Cell
proliferation occurs as a consequence ofthe
incompatibility of the allogeneic determi-
nants expressed on the surface ofthe two
lymphocyte populations. The test is per-
formed using murine or rat lymph node
cells. Single cell suspensions obtained from
mesenteric, inguinal, axillary, and cervical
lymph nodes are mixed with stimulator
cells that have been treated with mito-
mycin C. Mixed cultures are incubated and
3H-thymidine is added as described above
(8). Caution is needed to remove all traces
ofendotoxin from cell preparations.
A third method to assess CMI evaluates
NKcell function (9). NKcells are often the
first cell type to succumb to immunosup-
pression by a xenobiotic agent. They have
the natural ability to kill tumor cells, virus-
infected cells, and autologous monocytes
harboring intracellular bacteria. They are
effective against fungal invasion by rapidly
releasing cytokines that activate and recruit
neutrophils. NK cell dysfunction impairs
host defenses against viruses, bacteria,
fungi, and neoplasms.
Assessment ofNK cell function utilizes
cells obtained from the peripheral blood
and tumor cells previously labeled with
51Cr as the target cells. In the assay, rodent
cells obtained from the blood or spleen are
added to microtiter wells containing 51Cr
tumor cells (K562 for human NK activity
and YAC-1 for rodent NK activity). After
incubation at 370C for 4 to 6 hr, the super-
natant fluid is assessed for released 51Cr.
NK function is expressed as percent lysis at
aparticular effectorcell/target cell ratio.
Humoral Immune System
Assessment ofhumoral immunity, included
in tier I tests, typically uses the IgM antibody
plaque-forming assay. This measures the pri-
mary effector function, i.e. the synthesis and
secretion ofantigen-specific antibodies. This
test appears to be the most sensitive ofthose
developed to measure chemical perturbation,
and is the most commonly affected func-
tional parameter in animals exposed to
chemical immunosuppressants (5).
Mice receive intravenous or intraperi-
toneal administration ofsheep red blood
cells (SRBC) (10). Four days later, animals
are killed, and the spleen is removed and
separated into single cells. The cells are
mixed inwarmed agarwith an aliquotofthe
SRBC preparation used for immunization
and with guinea pig complement. The
mixture is then poured into a petri dish or
culture plate, covered, and incubated for 2.5
to 3 hr at 370C. The number ofplaque-
forming cells (PFC) is counted using a
viewer. Calculation is made ofthe number
ofPFC per spleen orper 106 spleen cells. As
described, the assay measures the pro-
duction of IgM antibody to SRBC.
Modifications to the procedure allow mea-
surement ofspecific IgG orIgAantibody.
ImmunePathology
Tier I also includes assessment of the
immunopathology ofkey organs ofthe test
animal. Blood, lymph nodes, bone marrow,
thymus, spleen, and mucosal-associated lym-
phoid tissues are examined. Morphology is
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noted and various stains are used to detect
changes in cellular function. Recent devel-
opments include molecular probes to detect
DNA damage, in situ hybridization to
detect gene activation, and magnetic reso-
nance imaging to allow evaluation ofthe
same tissue over aperiod oftime (11).
Tier 11
Compounds that test positive in tier I
assays are evaluated further to better define
the immunotoxic effect and to assess the
effect'cf the chemical on HR to an infec-
tious agent or tumor. Ifthe results oftier I
tests are negative, the chemical is consid-
ered not immunotoxic under the condi-
tions and in the dosages used in the
screening tests.
The selection of tier II tests is flexible
and depends on the nature ofthe immuno-
logic findings observed in tier I assays (5).
Tests frequently used in tier II analysis are
given in Table 1. Enumeration of the
lymphocyte populations within the spleen
(B and T cells) is performed using
fluorescent-labeled immune reagents to
detect cell surface antigens identifying B
cells (Ig) and T cells (Thy-1, Lyt-1,2,3)
and macrophages (MAC-1).
The HR assays allow detection ofthe
interactive function ofkey immune compo-
nents, including T and B lymphocytes,
macrophages, and the complement system
(12). For example, resistance to intracellular
microorganisms requires induction ofCMI
through Tlymphocyte-macrophage interac-
tion, production ofcytokines, and bacterici-
dal activity ofmacrophages. Resistance to
transplantable tumors is dependent on T
cell function and natural cytotoxicity.
Predictive Value ofTierTests
A study was performed to evaluate each of
the tests, and combinations oftests, in the
tier battery for immunotoxicity (Table 1)
for its ability to predict immunosuppres-
sion (6). The database for this analysis
consisted of over 50 chemicals that had
been tested by the National Institute of
Environmental Health Sciences, the
Chemical Industry Institute ofToxicology,
and the U.S. National Toxicology Program.
Individually, two tests were able to predict
immunotoxicity in rodents. The test that
had the greatest predictive power was enu-
meration ofthe lymphocyte populations
(based on cell-surface markers, 83% correct
predictions), followed by the PFC assay
(78% correct). The sensitivity ofthese tests
may be a result of relying on multiple
immune processes. The remaining tests in
the battery were not good predictors
ofimmunotoxicity.
Combinations oftests were examined to
determine their ability to identify immuno-
toxic chemicals (6). The combination of
the PFC response, or lymphocyte surface
marker determination, with almost any
other assay increased the ability to detect
immunotoxicity to greater than 90%. The
combination of PFC and surface markers
gave 91% accurate prediction. DTH alone
had poor predictability, but when coupled
with almost any other test, yielded high
predictivity. This suggests that DTH has
little functional interdependence with the
other tests in the battery (6). The findings
ofthe study suggest that some tests could
be deleted from the battery ofassays with-
out significantly decreasing the likelihood
ofidentifying a potential immunotoxicant.
A major issue that remains in the use of
these tests is that ofimmune system reserve.
Further information is needed about the
relationship between qualitative and quan-
titative changes in immune tests and devel-
opment ofclinical disease. The threshold
level in each test must be addressed in con-
sidering whether functional changes imply
clinical disease.
Nonhuman Primates
Immunotoxicity tests have been performed
using several nonhuman primates includ-
ing rhesus macaques, cynomologous mon-
keys, and marmosets. Most of the assays
involve blood or serum. In some models,
monoclonal antibodies to human leuko-
cytes can be used (13). Additionally, assess-
ment of DTH lymphocyte proliferation to
mitogens, NK function, and cytokine pro-
duction have been used to assess effects of
chronic exposure to Arochlor 1254 (13). It
is expected that use of these models will
increase with the availability of further
biotechnology products.
Immunotoxicity Assessment
in Humans
There are severe limitations to assessing
immune changes in humans. Noninvasive
tests must be used. Additional difficulties
indude establishment ofthe exposure dose,
and the continual background ofenviron-
mental exposures. Numerous factors con-
tribute additional heterogeneity in responses.
Immunological parameters are affected by
sex, gender, race, stress, medications, and
coexisting disease.
Testing schemes for preliminary evalua-
tion of individuals exposed to immuno-
toxicants have been proposed by several
organizations and agencies including the
World Health Organization, U.S. Centers
for Disease Control and Agency for Toxic
Substances and Disease Registry, and the
U.S. National Research Council (13).
Common features of the approaches are
inclusion of blood cell and differential
counts, assessment of lymphocyte pheno-
types, determination of immunoglobulin
levels or an antibody response, and assess-
ment ofautoantibodies or IgE. Additional
tests recommended by some ofthe agencies
include an assay for DTH and a measure-
ment ofnonspecific immunity, such as NK
activity orphagocytosis.
Interpretation of immunotoxicity test
results in humans is usually difficult. The
variation in human responses is great, fre-
quently exceeding a coefficient ofvariation
greater than 20 to 30% (13). It is recom-
mended that a positive diagnosis be based
on a pattern ofchanges, rather than on the
results ofany one test (13).
Animal Models of Host
Resistance
Host resistance models detect the effects of
chemicals on the functional integrity ofthe
immune system. Ideally, the model should
simulate a prevalent human disease, for
example, viral pneumonia. The test ani-
mals should be infected with a low dose of
infectious agent and by a natural route, to
avoid overwhelming the host immune sys-
tem (12). Mice are typically used because
offavorable cost, convenience, and knowl-
edge of immune system components and
interactions. Rarely is a single cell type
solely responsible for HR. Numerous
humoral and cellular responses contribute
to defense against microorganisms includ-
ing antibody production by B cells, cyto-
toxic T cells, NK cells, neutrophils, and
macrophages. Although there is redun-
dancy in the immune system such that
many components contribute to HR, some
are more important for particular infec-
tious agents than others. Several protozoan
parasites effectively stimulate antibody syn-
thesis, thus diverting the immune system
from a protective cellular response.
Both immunosuppression and immuno-
enhancement can be detected in HR mod-
els (12). A list ofthese models is provided
in Table 2. These assays are usually per-
formed by challenging the chemically
dosed animal with either an infectious
agent or a tumor. Challenge with extracel-
lular microorganisms, such as Salmonella
typhimurium, stimulates interaction of T
cells, B cells, and macrophages to produce
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Table2. Models ofhost resistance.
Microorganism Immune response
Listeria monocytogenes Delayed hypersensitivity; protection bymacrophages and Tcells
Streptococcuspneumoniae Acute pneumonia; protection byantibodyand complement
Plasmodium yoelii Elimination ofthe parasite requires B cells, Tcells, and macrophages
Syngeneic tumor cells Tcells and NK cells needed to resisttumorgrowth
(B16 F1O, melanoma)
(PYB6, carcinoma)
Trichinella spiralis Inflammation, expulsion of parasite; Tcells required, antibodies also involved
Influenza virus Mortality; antibody, interferon required
Murine cytomegalovirus Resistance tovirus proliferation; antibody, macrophages, NKcells required
91-
Table3. Models ofchemical hypersensitivity.
Dermal hypersensitivity
Local lymph node assay
Cutaneous basophil hypersensitivity
Guinea pig maximization test
Guinea pigdelayed contacthypersensitivity
Mouse earswelling test
Fluorescenceanalysis ofcell surface markers
Respiratoryhypersensitivity
Guinea pig inhalation model
Rat inhalation model
Mouse model
Fordetails ofassayprocedures, see Burleson etal.(4).
specific antibodies. Resistance to intra-
cellular organisms such as Lysteria mono-
cytogenes stimulates induction of CMI
through T cell and macrophage interaction
with production ofcytokines. Resistance to
transplantable tumors requires functional
activity ofT cells and NKcells.
TestsThat Correlate with
Host Resistance
Host resistance assesses the function ofthe
immune system in toto and from a risk
assessment point ofview is considered to
be the most relevant test ofimmunotoxic-
ity. The immune responses that contribute
to HR include humoral antibody pro-
duction by B cells, cytotoxic T cells, NK
cells, neutrophils, and macrophages. Both
immunoenhancement and immunosup-
pression can be detected with HR assays.
Insignificant changes in a number of
immune parameters may together result in
immunosuppression that lowers HR.
An attempt was made to develop a
mathematical model that would explain
the relationship between immune tests and
HR assays (12). The chemical selected was
cyclophosphamide, a well-recognized
immunotoxicant. Most of the immune
function tests showed a good correlation
with HR assays. There were no instances
where HR was altered without effects seen
in immune tests. However, there were cases
ofimmune test changes without effects on
HR. No single test was fully predictive for
HR. The best association was found with
DTH, whereas leukocyte counts and lym-
phoproliferative response were poor corre-
lates of HR. Concordance was increased
with combinations oftests. Pairwise com-
binations of PFC, surface markers, and
DTH gave greatest concordance.
Results from most ofthe immune func-
tion tests demonstrated alinear relationship
with those from HR assays. A linear dose
response implies that a slight change in the
immune test would reflect a change in HR
A linear quadratic response would follow
more closely a threshold model for risk at
low doses. Included in this category was the
surface marker determination. More analy-
ses such as these are needed to provide
insight into the relationship between assays
and HR. Such efforts would reduce the
need to perform many ofthe tests, while
improving the quantitative estimate of
immune riskfrom chemical agents.
Assessment of
Hypersensitivity
Hypersensitivity is a heightened immuno-
logic response that causes tissue distur-
bance, disruption, or death. The response
requires at least two exposures to the
causative agent. The first exposure primes
the system to respond; the second results in
the physiologic change or tissue damage.
Hypersensitivity reactions may be
mediated by antibody, with the frequent
result being a rapid response occurring
within minutes ofexposure. Alternatively,
reactions may be mediated by T lym-
phocytes, resulting in reactions occuring
up to 48 hr following contact with the
allergen (14).
The two majorhypersensitivity responses
to chemicals are contact hypersensitivity
and respiratory hypersensitivity. The assays
used to assess these responses are listed in
Table 3. Contact hypersensitivity is a
delayed-type skin reaction characterized by
cellular inflammation at the site ofexpo-
sure. Respiratory hypersensitivity is a
response of the respiratory tract. Those
responses that occur rapidly are believed to
be the result ofIgE antibody bound to spe-
cific receptors on mast cells and basophils.
Reexposure ofthe sensitized host to a previ-
ously encountered allergen results in cross-
linking of antibodies by the allergen,
degranulation of the cells, and release of
biologic mediators. The latter are respon-
sible for the vasodilatation and airway
constriction characteristic of respiratory
hypersensitivity. Late-onset respiratory
responses are recognized by a decrease in
FEV1 (forced expiratory volume in 1 sec)
and are associated with tissue inflamma-
tion, frequently rich in eosinophils (14).
The immunologic mechanism(s) responsi-
ble for the respiratory reaction to chemical
allergens islargely unknown.
Dermal Hypersensitivity
A wide variety ofchemicals cause dermal
(contact) hypersensitivity. Traditionally,
guinea pig tests have been used to identify
contact allergens; the most widely used test
is the guinea pig maximization assay (15).
The principle ofthis test is the elicitation of
erythema and edema in previously exposed
animals. Variations ofthe method include
intradermal or epicutaneous exposure,
occlusion ofthe test site, and incorporation
ofadjuvant at first exposure (induction). A
major disadvantage ofthe guinea pig test is
the subjective end point requiring visual
assessment oferythema. Other problems
arise from colored allergens and irritation
bythe agent.
Local IymphNodeAssay
This assay measures the induction phase of
the sensitization process and is based on
the assumption that the proliferative
response to first exposure correlates with
the sensitizing potential of the chemical
(i.e., the response to subsequent exposures)
(16). The assay is performed by applying
the test material to the ears ofCBA/Ca
mice on 3 consecutive days. Two days
later, 3H-thymidine is injected intra-
venously. Mice are sacrificed 5 hrlater, and
the draining auricular lymph nodes are
excised and pooled for each experimental
group. Radioactivity is counted in a scintil-
lation counter. The assay is based on the
finding that lymphocytes from sensitized
mice proliferate in vitro when cultured
with antigen-presenting cells displaying the
relevant antigen on their surfaces. Results
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are expressed as total counts or as a stimu-
lation index (comparison ofexperimental
with vehicle-treated animals).
Advantages ofthis test are its speed and
objective end point. Disadvantages are the
use of radiolabeled chemicals, and the
assumption that induction of an immune
response correlates with the elicitation
response. The method has undergone
validation studies and is appropriate as a
first-stage test in the assessment of skin
sensitization potential.
MouseEar-SwellingTest
The mouse ear-swelling test (MEST) was
designed to identify contact sensitizers by
measuring the inflammation associated
with the elicitation phase ofthe response.
This assay is based on the findings that
delayed-type contact sensitivity could be
transferred in the mouse through use of
thymus-derived cells.
The test is performed by topical appli-
cation ofthe chemical to the abdomen of
mice (17). Several days later, animals are
challenged on the ear with the chemical;
ear thickness is measured 24 and 48 hr
later. The increase in thickness when com-
pared to the control ear is a measure ofthe
contact hypersensitivity response. Variations
ofthe method indude injection ofadjuvant
at the induction site, irritation and abrasion
ofthe skin to increase absorption, multiple
induction applications ofthe chemical, and
supplementation ofthe diet with vitamin A
prior to testing (18). Alinear dose-response
effect was demonstrated with a variety of
contact sensitizers, including isocyanates
and formaldehyde (19).
Strengths ofthe test when compared
with traditional guinea pig tests are lower
cost, shorter duration ofeach test, less vivar-
ium space required, a more objective end
point, and the ability to monitor responses
ofcolored materials. The test has excellent
specificity but low sensitivity (17).
Difficulty may be encountered in interpret-
ing the response iffluid collects in the ear.
This test is appropriate as afirst-stage test for
the skin sensitization potential ofchemicals.
FluorescentAnalysisofCeli
SurfaceMarkers
This method evaluates the surface antigens
ofthe mononuclear cells associatedwith the
contact hypersensitivity lesion. In addition
to surface markers, cell cycle and activation
states can be assessed through the use of
specific fluorescent-labeled reagents (20).
The advantage ofthis method is its ability
to analyze thousands of cells by several
parameters. Increases in CD4 T lympho-
cytes were shown following sensitization
with dinitrochlorobenzene.
B6C3F, mice are sensitized by epicuta-
neous exposure on several consecutive days
near the shoulder blade. Ear challenge is per-
formed on days 14 to 16. The ears are har-
vested 24 to 48 hr later, and cells dispersed
and prepared for staining with reagents that
may include L3T4 (CD4), Lyt-2 (CD8), or
B220 (CD45RA, specific for B cells). Results
have generally mirrored those obtained with
MEST analysis. Analyses have indicated that
CD4+ cells, but not CD8+ cells, are signifi-
cantly increased at the elicitation site on
days 1 and 2 after challenge. A difference
was noted in cells in the lymph nodes
following challenge when compared with
those in sensitized, nonchallenged animals.
Nonchallenged animals demonstrated more
CD8+ cells on day 3 when compared with
challenged animals.
RadioisotopeMethodtoAssess
AliergcContatDermatids
This method addresses the potential prob-
lem with MEST that fluid buildup rather
than increased cellularity may be detected.
Use ofa radioisotopic assay permits mea-
surement of inflammatory cells with
increased sensitivity and objectivity. The
procedure utilizes B6C3F, mice and
sensitization is similar to that described for
the flow cytometric procedure (21). On
day 8, animals are injected in the tail vein
with '251-BSA and challenged on the ear
with the test chemical. Three hours later,
ears are biopsied to measure irritancy. For
evaluation ofACD, 125I IUdR is injected
after treatment; 48 hr later ears are taken
and counted.
Weak sensitizers pose a problem for this
assay. Compared with MEST, the method
was more sensitive in revealing activity of
glutaraldehyde, but less sensitive with 2-
mercaptobenzothiazole. Dietary supple-
mentation with vitamin A may increase
sensitivity as it has with MEST.
Respiratory Hypersensitivity
Respiratory hypersensitivity is diagnosed in
humans by a decrease in FEV1 after expo-
sure to the agent (14). For proteins and
other high molecular weight materials, the
response is believed to be ofimmunologic
origin; for low molecular weight materials
such as industrial chemicals the mechanism
remains unclear (14).
Mechanistically, responsiveness to high
molecular mass allergens is usually attributed
to allergen-specific IgE. Animal models have
been developed to better understand the
pathogenesis ofthe disorder and to compare
potencies oftest agents, largely proteins. As
reviewed by the author (22), a variety of
species has been utilized including mice, rats,
guinea pigs, rabbits, dogs, sheep, horses, and
nonhuman primates. Differences among the
models indude animal species utilized, route
ofadministration ofthe agent, protocol for
induction and elicitation ofresponses, type
ofresponse measured, and judgment ofa
significant response.
Low molecular weight (LMW) aller-
gens (< 1 kDa) are considered too small to
stimulate an immune response, but are
capable of this activity when chemically
associated with a large molecule, such as
serum albumin, as a hapten (14). Models
ofrespiratory sensitization by LMW agents
include the guinea pig, mouse and rat
models, and the mouse IgE model (22).
GuineaPigModel
Guinea pigs have been the species ofchoice
for predictive models ofrespiratory hyper-
sensitivity. The inhalation model (23) and
the intratracheal model (24) rely on the
physiologic respiratory response ofanimals
to challenge with the sensitizing agent, as
well as on the production of allergic anti-
body. These models have been calibrated
to human sensitization through the use of
detergent enzyme allergens, for which there
are good human exposure and response
data (24).
Guinea pig methods for measurement
ofchemical-induced respiratory allergy also
rely upon the inhalation route for both the
induction and elicitation phases of reac-
tion. Elicitation of the response to respira-
tory challenge is performed with the
chemical, or with a protein conjugate of
the chemical (23). Less emphasis is placed
on the production ofallergic antibody, as
few chemicals induce such antibodies in
humans, and it is uncertain if antibodies
have a role in the sensitization response.
The inhalation model was developed for
use with toluene diisocyanate (25), and has
been applied successfully to the study of
other isocyanates and some acid anhy-
drides. It was not able to detect sensitiza-
tion to some reactive dyes (23), although
allergic antibodywas produced to the latter.
Drawbacks of the guinea pig models
include the cost of the studies and the
technical expertise required to generate
and monitor atmospheres of reactive
chemical sensitizers and to monitor
respiratory responses in challenged ani-
mals. These methods were developed
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mainly for investigational purposes and
not for routine screening.
MouseModel
A mouse model has been described to
assess the relative allergenicity ofproteins
and polypeptides (26). The benchmark
allergen used to compare responses is the
protease, subtilisin. Intranasal and intratra-
cheal dosing have been used. Specific anti-
bodies are measured as a function of the
dose ofantigen administered, the dosing
matrix, and the isotype ofantibody pro-
duced. Using subtilisin, peak antibody
responses were observed after 6 to 8 weeks
ofdosing. Detergent administered with the
allergen augmented the TgG1 responses
approximately 4-fold. IgE responses were
inconsistent. Differences in potencies of
proteins paralleled findings with the guinea
pig model. Compared with the guinea pig
method, the murine system has the advan-
tage of lower cost, easier handling, and
need for less material.
Mouse IgE Test. The primary reason
for development ofthe assaywas for predic-
tive purposes, rather than for mechanistic
studies (27). The method is based on the
assumption that respiratory allergens stimu-
late a Th2 lymphocyte response in mice,
whereas contact allergens would provoke a
Th, response. Th, cells secrete IL-2 and
interferon y, whereas Th2 cells secrete IL-4
and IL-10. The latter cytokines stimulate
production ofIgE.
The assay is performed by repeatedly
exposing mice epicutaneously to the chem-
ical; usually three concentrations are used.
After an interval ofseveral weeks, serum is
taken for evaluation ofIgE and cytokines.
This method remains to bevalidated by
independent laboratories. Potential advan-
tages of the method are cost and speed.
Because nonspecific IgE is measured, there
is no need to prepare hapten conjugates for
detection ofspecific antibodies.
TheRatModel
A rat model assesses chemical allergens by
measurement ofairway inflammation (28).
Animals are exposed via nose-only inhalation
to the chemical for 1 or 2 consecutiveweeks.
Histologic assessment is made ofrespiratory
tissue. Findings have included eosinophilic
inflammation, secretory cell hyperplasia,
epithelial desquamation, mucus plugs and
cellular debris in the airway lumen, and
smooth muscle hypertrophy. Regression of
disease is monitored byphysiologicresponses
during an observation period of 1 to 2
months after cessation ofexposure.
For all models, validation is needed
using both positive and negative chemi-
cals. Moreover, the sensitivity ofthe meth-
ods in comparison with human data must
be addressed.
Assessment ofAutoimmunity
Autoimmune disease represents a significant
dinical problem in thatapproximately 5% of
the U.S. population is affected. Moreover, as
the population ages, the likelihood ofan
increase in prevalence is expected. Genetics
plays a large role in susceptibility to autoim-
mune disease, and environmental factors
influence disease development. Infection is
the most frequently cited environmental
agent. Physical factors such as ionizing radia-
tion and sunlight have been cited, as have
therapeutic drugs. Penicillamine has been
associatedwith cases ofmyasthenia gravis.
Animal models have been described
for experimental induction of auto-
immune disease (29). However, these
models are used mainly to elucidate the
pathogenesis ofautoimmunity rather than
for toxicologic assessment.
There are several mechanisms associated
with autoimmunity (29). Release ofanti-
gens that are normally segregated from the
immune system, for example, the lens ofthe
eye, can initiate the process. Asecond mech-
anism relies on molecular mimicry. This
process is based on the observation that
antigenic determinants in the bodyare often
replicated on foreign antigens. Beta hemo-
lytic streptococci possess membrane deter-
minants that resemble antigens of the
cardiac myocyte. Molecular mimicry may
also occur when changes are induced on
endogenous antigens. Altered self-molecules
are partially foreign and may be recognized
as foreign by the immune system. Viruses
may attack the reticuloendothelial system
and alter immune recognition or regulation
ofcell populations. It must be emphasized,
however, that although autoantibodies may
beproduced, theydo notimplydisease (29).
Risk Assessment
The guinea pig intratracheal model has
been used for assessment ofrisk for respi-
ratory hypersensitivity from protein aller-
gens (30). For LMW chemicals, hazard
identification can involve structure-activ-
ity relationship (SAR) analyses or assess-
ment ofelectrophilicity such as the ability
of the chemical to haptenate a protein or
peptide. For either, determination of
specific antibody production after injec-
tion into animals has also been used for
hazard identification.
Dose-response data can be obtained
from the guinea pig models. Calibrations
ofthe animal model to human response are
performed using benchmark chemicals for
which there is both human and animal
data (24). One example is hypersensitivity
to the protease subtilisin. Antibody titers
and pulmonary responses to atmospheric
levels ofthis enzyme are known for animals
and for humans. In both, specific antibody
is produced at allergen concentrations
lower than those required for induction of
pulmonarysensitivity.
For LMW allergenic chemicals, bench-
mark chemicals for which there are guinea
pig and human data of sensitization are
toluene diisocyanate and trimellitic anhy-
dride (24). Because the U.S. threshold
limit value (U.S. TLV) for each chemical
appears to protect against sensitization,
dose-response data obtained from animals
can be compared with the human TLV to
calibrate the two systems.
Risk assessment for immunosuppression
should be subjected to the same principles
as that for other disciplines. Toxicokinetics
should be studied to evaluate exposure lev-
els obtained in animals and relate this to
expected human levels. The rat and mouse
tier systems were adequate in identifying
the immunotoxic hazard ofazathioprine
and cyclosporine, compounds that are
potent immunomodulators in rodents and
humans (13). The problem is difficult for
compounds that exert subtle effects in
rodents. In such cases, HR assays will gain
importance. However, no single HRmodel
will suffice as each model requires different
components of the immune system to
work in concert. It is ofgreat importance
to knowwhether increases in host suscepti-
bility to immune challenges follow a
thresholdlike or a nonthreshold model as a
function of immunosuppression (13).
Additionally, immune reserve may be
applicable to individuals, but in popula-
tions where immunocompetence may be
compromised because ofchronic disease,
immunoreserve may not beapplicable.
Expected Advances
The multicomponent nature of the
immune system has driven the develop-
ment of numerous tests to assess its indi-
vidual components as well as its integrated
functioning. With the current focus on
reduction and replacement ofanimal use in
toxicology, alternative methods to standard
mammalian models are emerging to assess
immune status after chemical exposure.
There is a trend toward the use offewer
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Table 4. Future developments in assessment of
immunotoxicity.
In vivomodels
Use offewer, butmore predictive tests
Histopathology: gene activation, DNA damage, in
situhybridization, magnetic resonance imaging
to detectchronic effects
Lymphoid organs: popliteal lymph node assay, bone
marrowcell assays
Flowcytometryforcell enumeration and functional
assessment
Use offeral animal models, i.e., fish
In vitrosystems
Hapten-protein association assays
Cell cultures: cytokine assays
Computational structure-activity models
Mechanistic and predictive models
but more predictive tests (Table 4; section
on Predictive Value ofTierTests).
New animal tests are being developed as
screening assays to detect autoimmunogenic
chemicals, most frequently in drug assess-
ment. One promising method is the
popliteal lymph node assay (16) which can
be performed in mice and rats. The assay
measures activation ofthe draining lymph
node ofthe hind paw after injection ofthe
test agent into the hind foot pad. The
method has beenable to detectpharmaceuti-
cals prone to induce systemic autoimmune-
like reactions in an early stage ofpredinical
testing. Themethod requiresvalidation.
Fish Models
The use ofnonrodent species for immuno-
toxicologic evaluation of chemicals has
gained attention. Fish models have been
described to assess the effects ofenviron-
mental pollutants on the immune system
(31). Fish do not have bone marrow or
lymph nodes, but possess hematopoietic
tissues functionally equivalent to that of
mammals. Their circulating white blood
cells are capable ofphagocytosis and of
rejecting allografts. Fish can exhibit inflam-
mation and hypersensitivity responses,
synthesize specific antibody, respond to
mitogens, elicit a MLR, process and pre-
sent antigens, and release biologic media-
tors such as interleukins, cytokines and
arachidonic acid metabolites (31). In addi-
tion, fish demonstrate immunologic toler-
ance and memory (more rapid and
stronger response to a second contact with
antigen). Chemicals that are immunotoxic
in mammals and also immunotoxicants in
fish are lead, nickel, organochlorine and
organophosphates, pesticides, halogenated
aromatic hydrocarbons, and polycyclic
aromatic hydrocarbons (31).
Advantages offish systems include their
large size (resulting in plentiful cells), easy
maintenance in the laboratory, andlowcost.
Disadvantages are dosing regimens, and cur-
rent limited knowledge ofthe immune tis-
sues and mediators. Data are needed to
evaluate the sensitivity ofthe fish immune
system compared to thatofhumans.
Computational Toxicology
Methodology
Several in vitro and in vivo models have
been developed for predictive testing ofsen-
sitizers. For respiratory chemical sensitizers,
focus has been on theabilityofthe chemical
to bind to a protein. Shortcomings with this
methodology are that the procedures iden-
tify electrophiles and nucleophiles, but not
all sensitizers belong to these classes (32).
Further, not all electrophiles and nucle-
ophiles are sensitizers. Thus, such tests are
neither sufficiently sensitive nor specific for
predictive purposes. SAR models have been
reported for both respiratory and dermal
chemical sensitizers (33). For contact sensi-
tivity, several SAR models have accurately
predicted strong-moderate sensitizers by
identifying electrophiles, nucleophiles, pro-
electrophiles, and pronucleophiles (34).
The CASE/MultiCASE artificial intelli-
gence system has moderate success in identi-
fying weak sensitizers (34). This latter
system differs from others in that itdoes not
assume a mechanism ofsensitization, but
rather operates from identification ofstruc-
tural fragments thathave astatistical associa-
tionwith the dass ofsensitizing chemicals as
comparedwith non-sensitizing chemicals.
An SAR model for respiratory chemical
sensitizers has been described (2,33). The
data base consists of chemicals identified
from human case reports. The model has
identified chemical fragments associated
with activity. The model is expected to
enable predictions ofrespiratory sensitiz-
ing capacity ofchemicals, as well as pro-
vide mechanistic insight into the process
ofsensitization.
Current investigations employing
computational models are considering
chemical fragments and physical-chemical
features ofchemicals, as well as their meta-
bolic conversions, for predictive purposes.
It is anticipated that future SAR models
will tackle the problem of predicting
immunotoxicity from exposure to mixtures
ofchemicals.
Molecular Methodology
Methods for identification ofgenes and
regulatory elements in cells are expected to
aid in identification ofsusceptible indi-
viduals. Such tools will also identify cell
activation stages, and markers ofoxidative
stress. Identification ofgenes involved in
asthma and allergy will guide mechanistic
studies, as well as have application to the
development ofdrugs and otherapproaches
for treatment.
Biomarkers
Cytokines are glycoproteins that are
produced and secreted by cells in response
to cellular activation. Their production is
regulated at the transcriptional and post-
transcriptional levels. They appear to be a
central factor governing the induction and
regulation ofimmune responses and have
considerable potential as biomarkers of
immune toxicity. Further epidemiologic
studies are needed to clarify the usefulness
ofbiomarkers fordetectingimmunotoxicity
andhealth outcomes.
Validation
There must be validation ofthe tests that
evaluate immunotoxicity. The goal of
validation is to determine which methods
should be recommended in the testing
guidelines ofregulatory agencies. Validation
consists oftesting a set ofcompounds with
known positive and negative immunotoxic-
ity and determining the sensitivity, speci-
ficity, accuracy, and precision ofthe tests
(13). These parameters are defined as sensi-
tivity, the ability to identify positive chemi-
cals; specificity, the ability to identify
negative chemicals; accuracy, the ability to
measure the intended end point; and preci-
sion, the ability to reproduce results. Some
test methods have undergone validation as
described in previous sections ("Predictive
ValueofTierTests" and "RiskAssessment").
However, consideration mustbegiven to the
question ofwhethervalidation requires com-
pounds to be shown to be immunosuppres-
sive inhumans aswell as in rodents.
Conclusions
Trends are emerging among the newer
methods being developed for immuno-
toxicitytesting. Prominent among the trends
is less use ofwhole animals, more in vitro
tests, more use ofcomputational methods,
and greater interest in in vitro mechanistic
assays. As progress is made in understanding
the regulatory relationship among immune
system components and in gaining mecha-
nistic understanding ofimmunotoxicity,
greater use ofcell number determinations,
cell surface and functional antigens, and
simple focusedassays is predicted.
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